Phase II Study of Biweekly Plitidepsin as Second-Line Therapy for Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Phase II Study of Biweekly Plitidepsin as Second-Line Therapy for Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

The objective of this exploratory, open-label, single-arm, phase II clinical trial was to evaluate plitidepsin (5 mg/m2) administered as a 3-hour continuous intravenous infusion every two weeks to patients with locally advanced/metastatic transitional cell carcinoma of the urothelium who relapsed/pr...

Full description

Bibliographic Details
Main Authors: Sergio Szyldergemajn, Jean P. Droz, Sonia Extremera, Patrick Schöffski, Joan Carles Galceran, Enrique Gallardo, Stephane Culine, Aude Fléchon, Herlinde Dumez
Format: Article
Language:English
Published: MDPI AG 2009-09-01
Series:Marine Drugs
Subjects:
plitidepsin
TCC
urothelium
second-line
transitional cell carcinoma
Online Access:http://www.mdpi.com/1660-3397/7/3/451/

Similar Items

Similar Items